

DVHA

Pharmacy Newsletter

News and Updates

November 2018

IN THIS ISSUE

Changes to Coverage for Actavis (Labeler 00591)

Synagis 2018/2019 Season Prior Authorization

20018/2019 Influenza Season

Administration Fee for Influenza Vaccine

Suboxone® Film Requirements

Legislative Changes

eWEBS Pharmacy Provider

Welcome Lisa Brouillette Hurteau, Pharm D

DUR Board Members

<u>Important Changes to Coverage for Actavis (Labeler 00591) Authorized</u> Generic of Concerta

Effective 1/1/19, the Actavis (labeler 00591) authorized generic for Concerta® (methylphenidate HCI) will be moving to non-preferred status on the Department of Vermont Health Access (DVHA) Preferred Drug List (PDL). To view this notification in its entirety please go to http://dvha.vermont.gov/for-providers/concerta-ag.pdf

Synagis 2018/2019 Season - Prior Authorization

For the 2018/2019 season, DVHA will authorize any pharmacy that is part of the Vermont Medicaid specialty pharmacy network to dispense Synagis® (palivizumab). To view this notification: DVHA-enrolled specialty pharmacies please go to http://dvha.vermont.gov/for-providers/synagis-2018-final.pdf

Influenza (Flu) 2018/2019 Season provider notification

DVHA-enrolled pharmacies may be reimbursed for injectable influenza vaccinations administered by pharmacists to adults 19 years and older who are enrolled Vermont's publicly funded programs. To see covered vaccines please go to http://dvha.vermont.gov/for-providers/influenza-2018-19-provider-notice-final.pdf

Important Changes to Administration Fee for Influenza Vaccine

Effective 8/31/2018, the pharmacy administration fee for influenza vaccines will be changing from \$20.35 to \$16.71. This adjustment is being made to align with changes to the physician fee schedule (CPT code 90471) for adult vaccinations. Pharmacies will continue to be reimbursed for the ingredient cost of the vaccine as well as the administration fee. The same administration fee will be paid for both in-state and out-of-state pharmacies. Through the pharmacy point-of-sale (POS) system, the pharmacy must submit the code "MA" in the Professional Service Code field to receive full reimbursement.

Additionally, the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC) have published their official recommendations for the 2018/2019 influenza season which can be found at https://www.cdc.gov/mmwr/volumes/67/rr/rr6703a1.htm

Suboxone® Film Requirements

DVHA is removing prior authorization (PA) requirements for our preferred product, Suboxone® Film, when the maximum daily dose does not exceed 16mg, effective 10/12/18. To view this notification in its entirety please go to: http://dvha.vermont.gov/for-providers/suboxone-preferred-final.pdf

Legislative Changes Affecting Medicaid

A communication from the Board of Pharmacy clarified that Act 193, signed into law May 2018, amends Section 2 18 V.S.A. 4605 to include selection by a pharmacist of the lowest-priced interchangeable biological product when filling a prescription for biological product. Act 193 further clarifies that pharmacists should follow the Medicaid PDL for both generics and biological products. To view this notification in its entirety please go to: http://dvha.vermont.gov/for-providers/pharmacycommunicationpdlact193-final.pdf

eWEBS Pharmacy Provider Portal

The eWEBS Pharmacy Provider Portal has been available since May 2018. Features available to all registered pharmacy managers and prescribers include: member inquiry, pharmacy inquiry, formulary inquiry, diagnosis inquiry and program alerts, announcements and updates.

Pharmacy managers can authorize other pharmacy staff to have access to the eWEBS Provider Portal for member PA look up, eligibility inquires and member drug profile history through the portal's "Delegate Management" functionality.

You can access the portal via https://providerportal.vtgov.emdeon.com/vtpp/application/login.joi and follow the directions. To submit the enrollment form. You will be issued a user ID and password once your registration information has been submitted and validated. For full article http://dvha.vermont.gov/for-providers/lewebs-notificaiton-final.pdf. If you have questions about the portal email Nancy Miner at https://www.vermont.gov/for-providers/lewebs-notificaiton-final.pdf. If you have questions about the portal email Nancy Miner at https://www.vermont.gov/for-providers/lewebs-notificaiton-final.pdf. If you have questions about the portal email Nancy Miner at https://www.vermont.gov/for-providers/lewebs-notificaiton-final.pdf. If you have questions about the portal email Nancy Miner at https://www.vermont.gov/for-providers/lewebs-notificaiton-final.pdf.

DVHA Pharmacy Unit Staff Announcement

Please welcome our new Clinical Pharmacist, Lisa Brouillette-Hurteau, Pharm.D., to the DVHA Pharmacy Unit! As a Clinical Pharmacist, Lisa will be involved in the clinical management and support of the publicly funded pharmacy benefit programs. Lisa is a native Vermonter and completed her B.S. in Biology at Stonehill College and Doctor of Pharmacy at Albany College of Pharmacy. Lisa is a licensed pharmacist in the State of Vermont and has worked in retail pharmacy for several years, where she enjoyed working in medication therapy management and immunization management. Lisa is also a board-certified geriatric pharmacist.

Drug Utilization Review (DUR) Board Members

We are pleased to announce Claudia Berger, M.D., as our newest DUR Board member. Claudia graduated from Albert Einstein College of Medicine in 1991 and completed her residency with the University of Vermont College of Medicine in 1994. Claudia is board certified in Internal Medicine. More information about the DUR Board can be found on this link: http://dvha.vermont.gov/advisory-boards